State Street Corp. Updates Passive Stake in BridgeBio Pharma
Ticker: BBIO · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**State Street still owns BridgeBio stock, signaling continued institutional interest.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of BridgeBio Pharma, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, confirming their continued significant, though passive, stake in BridgeBio Pharma. This matters to investors because it shows a large institutional investor maintains a position, which can signal confidence in the company's long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.
Why It Matters
This filing confirms a major institutional investor, State Street Corporation, continues to hold a significant, passive stake in BridgeBio Pharma, which can be a positive signal for other investors.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate risk or significant change in company fundamentals.
Analyst Insight
An investor should note that a large institution like State Street Corporation maintains a position in BridgeBio Pharma, suggesting continued institutional confidence, but should also look for the specific percentage of ownership in the full filing to gauge the magnitude of their stake.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- BridgeBio Pharma, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, indicating a change or update to previously reported beneficial ownership of securities.
Who is the reporting person in this filing?
The reporting person is State Street Corporation, identified by CIK 0000093751 and IRS Identification No. 04-2456637.
What is the subject company whose securities are being reported?
The subject company is BridgeBio Pharma, Inc., identified by CIK 0001743881, with common stock as the title of the class of securities.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Under which rule was this Schedule 13G/A filed?
This Schedule 13G/A was filed under Rule 13D-1 (B), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding BridgeBio Pharma, Inc. (BBIO).